Breast Cancer Foundation NZ
AVATAR
Advanced Breast Cancer clinical trials for ER+
This study will investigate the effect of stereotactic radiotherapy to see whether it helps women with ER+, HER2- advanced breast cancer continue CDK 4/6 treatment for longer.
This study will investigate the safety and efficacy of stereotactic radiotherapy treatment in combination with aromatase inhibitor and CDK4/6 inhibitor for advanced breast cancer. This research will give researchers information about whether adding radiotherapy to a CDK4/6 inhibitor increases the amount of time participants can stay on CDK4/6 inhibitor therapy.
Who is it for?
You may be eligible to join this study if you are aged 18 and above, have histologically proven ER+, HER2-advanced breast cancer with metastases and receiving an aromatase inhibitor in combination with a CDK 4/6 inhibitor.
Study details
All participants in this study receive stereotactic radiotherapy (between one to five doses as ascertained by treating doctor after consultation) in combination with prescribed aromatase inhibitor and CDK 4/6 inhibitor.
Participants will be monitored for reactions and treatment effectiveness, and provide blood and urine for analysis throughout the two-year study.
Australia
The Canberra Hospital, Canberra
Monash Medical Centre, Melbourne
Peter MacCullum Cancer Centre, Melbourne
St Vincent's Hospital, Melbourne
The Townsville Hospital, Townsville
Contact:
Suzie RoacheIf you think you might be a candidate for this trial, use the contact details supplied, or talk to your doctor.
Want to access a trial that's not in your area? It's not always possible, but if you're interested, email us at intouch@bcf.org.nz
Similar clinical trials
For Advanced Breast Cancer
Are we out of date? If you have updated or new information about a trial, we’d be grateful if you’d share it with us – email your update to intouch@bcf.org.nz
Interested in a clinical trial?
Subscribe for updates & stay in the loop with new studies.